The prognostic value of NLR for early death in secondary Hemophagocytic lymphohistiocytosis patients: an analysis of 92 patients

linhui hu  
Second Affiliated Hospital of Anhui Medical University

fan wu  
Second Affiliated Hospital of Anhui Medical University

Ying Pan  
second affiliated hospital of anhui medical university

jiakui zhang  
Second Affiliated Hospital of Anhui Medical University

qian li  
second affiliated hospital of Anhui Medical University

weiwei zhu  
second affiliated hospital of anhui medical university

chen ding  
second affiliated hospital of anhui medical university

ye meng  
second affiliated hospital of anhui medical university

huiping wang  
second affiliated hospital of anhui medical university

shudao xiong  
second affiliated hospital of anhui medical university

zhimin zhai (✉ zzzm889@163.com)  
Second Affiliated Hospital of Anhui Medical University  https://orcid.org/0000-0003-0950-8364

Research

Keywords: Hemophagocytic lymphohistiocytosis, NLR, mortality

DOI: https://doi.org/10.21203/rs.3.rs-49016/v1

License: ©️ This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background: Hemophagocytic lymphohistiocytosis (HLH) a hyperinflammation disease and have high early mortality. The neutrophil-lymphocyte ratio (NLR) plays a prognostic role in various inflammation conditions. However, the role of NLR in HLH remains unknown.

Results: 92 patients were collected from Sep 2014 to Dec 2019, the median age was 50 years (16-88) and 54 patients (58.6%) were male. 39 patients (42.3%) died during a 30-day follow-up. In addition, NLR was higher in nonsurvivor than survivor (P=0.005), higher NLR was correlated with older age (P=0.020), worse survival status (P=0.006), lower HB level (P=0.008), longer PT level (P=0.010), higher creatinine level (0.027) and higher IL-6 level (P=0.008) and in multivariate analysis, NLR (HR=2.508, 95%CI: 1.275-4.934), was indicated as an independent prognostic factor for early death.

Conclusions: NLR was correlated with early death in HLH, suggest NLR could be used as a reference indicator for the monitoring and management of HLH.

Background

Hemophagocytic lymphohistiocytosis (HLH) is a rare but life-threatening syndrome. HLH is characterized by an uncontrolled immune response and persistent activation of cytotoxic T lymphocytes and natural killer cells, subsequently excessed secretion of inflammatory cytokines and macrophage activation, leads to cytokines release storm, systemic inflammation and multiple organ failure[1, 2]. The following manifestations are usually observed in patients with HLH: fever, enlargement of the liver and the spleen, cytopenias, liver dysfunction, increased triglycerides and ferritin and hemophagocytosis in bone marrow, the liver, the spleen or the lymph nodes.[1-3]

HLH can be observed in all ages and categorized into primary HLH and secondary HLH according to the underlying triggering condition. Primary HLH is a familial inherit disease with an autosomal recessive form; secondary HLH often caused by infections, malignancy, and autoimmune/autoinflammatory disease [4, 5]. The clinical application of HLH-94 and HLH-2004 protocol decreased the overall mortality of primary HLH[6, 7], however, the specific treatment for secondary HLH is limited, and the early mortality remains high[8], it is urgent to stratifying high-risk patients, and initiate appropriate therapy in these patients[3, 9]. Therefore, a usefulness indicator of early death is needed.

Recently, a simple, rapid, inexpensive marker, the neutrophil-lymphocyte ratio (NLR) was suggested to be a robust biomarker of systemic inflammation and predicts early death and overall survival in various inflammation associated pathological conditions[10-13]. It is well known that increased neutrophil counts represent systemic inflammation and decreased lymphocyte counts represent the immune system[10], the combination of neutrophil and lymphocyte makes NLR as a more comprehensive biomarker. However, the prognostic value of NLR in HLH, a hyper-inflammation disease, remains unknown. In this study, we retrospectively analyzed a cohort of 92 patients with secondary HLH and analysis the associated of NLR and HLH 30-day mortality.

Results
**Characteristics of patients**

A total of 92 patients were included in our analysis, the median age at diagnosis of them was 50 years, ranged from 16-88, and 54 patients (58.6%) were male.

Regarding the triggering condition, 48 patients (52.2%) secondary to malignancy, 27 patients (29.3%) secondary to infections, 10 patients (10.9%) secondary to autoimmune disorders, and the underlying triggering disease of 7 patients (7.6%) were unknown. In addition, we analyzed the triggering condition according to age and gender, malignancy was the mainly triggering condition in all subgroup, the distribution was shown in Figure 1.

51 patients (55.4%) received only glucocorticoid therapy, 32 patients (34.8%) received glucocorticoid combined with etoposide, and 9 patients (9.8%) did not receive any special treatment for hemophagocytic syndrome and were only treated with supportive symptomatic treatment.

**Patients Characteristics according to survival status and NLR**

After diagnosis and initial treatment, all patients were followed up for at least 30 days. In our cohort, 39 patients died with a mortality of 42.3% after 30 days of observation. Patients were divided into two groups according to survival status, and the patient's characters, complete blood counts, NLR, biochemical indicators, and underlying triggering condition were compared. There was significant difference in age, lymphocyte counts, NLR, PLT, PT, APTT, FIB, Albumin, Creatinine, LDH, and splenomegaly (Table 1). Nonsurvivor were associated with elder (P=0.04), lower lymphocyte counts (P=0.001), lower PLT counts (P=0.019), lower FIB level (P=0.024), lower albumin level (P=0.008), higher NLR (0.005), longer PT level (P=0.005), longer APTT level (0.002), higher creatinine level (P=0.017), higher LDH level (P=0.035) and splenomegaly (P=0.02), respectively.

Furthermore, patients were also divided into two groups according to NLR median value, and higher NLR was correlated with older age (P=0.020), worse survival status (P=0.006), lower HB level (P=0.008), longer PT level (P=0.010), higher creatinine level (0.027) and higher IL-6 level (P=0.008) (Table 1), in addition, NLR were correlated with the length of survival (spearman correlation=-0.252, P= 0.016).

**Univariate analysis for 30-day-mortality**

To further identify the potential indicators, cox regression was employed to identify the potential prognosis factors for 30-day-mortality. As shown in Table 2, $L \geq 0.62 \times 10^9/L$ (HR=0.427, 95%CI:0.219-0.833), $NLR \geq 2.99$ (HR:2.396, 95%CI:1.230-4.669), $PT \geq 13.3s$ (HR:2.620, 95%CI:1.303-5.269), $APTT \geq 39.5s$ (HR:2.701, 95%CI:1.366-5.340) and albumin$\geq 26 g/L$ (HR:0.346, 95%CI: 0.175-0.685) could be used as prognostic factors for 30-day-mortality.

**Multivariate analysis for 30-day-mortality**

In multivariate analysis, $NLR \geq 2.99$ (HR=2.508, 95%CI: 1.275-4.934) and $APTT \geq 39.5s$ (HR=2.780, 95%CI: 1.395-5.542) were associated with a poorer prognosis, albumin$\geq 26g/L$ (HR=0.384, 95%CI: 0.192-0.768) was associated with a better prognosis, and could be used as independent predictors for 30-day-mortality (Table 3). In addition, the Kaplan-Meier curve according to NLR, APTT, and albumin were shown in figure 2.
Discussion

In this study, we analyzed the potential prognostic value of NLR for 30-day mortality in a cohort of 92 patients with secondary HLH, and found that NLR was higher in nonsurvivor patients, in addition, a higher NLR was associated with increased 30-day mortality, and multivariate analysis indicates NLR was an independent predictor of 30-day mortality. To our best knowledge, this is the first study that investigates the relationship between NLR and the early death of HLH.

Based on the evidence published to date, secondary HLH was mainly secondary to malignancies and infections, and male patients had a higher incidence compared with female patients. Due to the rapidly progressing and limited specific treatment, secondary HLH had high early mortality, which ranged from 20.4% to 43.4%[4, 14-16], our result was consisted with it. Given this, it is necessary to carry out a usefulness indicator to stratifying patients.

In recent years, NLR as an inflammation indicator has been well studied in various inflammation associated pathological conditions[10-13]. Higher NLR was correlated with more advanced disease stage in autoimmune disease[17, 18] and it was proved to be an independent prognosis factor in infections disease[11, 19], diffuse large B-cell lymphoma[20, 21], and so on. Whilst, a higher NLR predicts increased 30-day mortality in critically ill patients[13, 22, 23]. In this study, we observed that nonsurvivor had a higher NLR compared with survivor, and higher NLR was correlated with older age, longer PT, higher creatinine, and lower HB. In addition, the univariate analysis identified the prognostic value of NLR, and multivariate analysis proved NLR was an independent prognosis factor for 30-day mortality. Above all, NLR is a reliable indicator to predict the early death in HLH.

The mechanism underlying the association of higher NLR and increased mortality in HLH patients remains unknown, we hypothesis that, on the one hand, the correlation between NLR and proinflammatory cytokines endowed the prognostic value of NLR. In HLH, excessive secretion of cytokines leads to local and systematic inflammation, tissues damage and organs failure, and higher measured cytokine levels was correlated with poorer outcomes[1, 24]. Published data indicated that NLR has a positive correlation with proinflammatory cytokines, such as interleukins (IL-1ra, IL-6, IL-7, IL-8, IL-9, IL-12), interferon γ and macrophage inflammatory protein 1β[10]. And in our study, a positive correlation between NLR and IL-6 was also observed. On the other hand, the prognostic value of NLR may result from the relationship between NLR and dysregulated immune response (decreased NK cell activity and increased CD8+ T cell). Evidence indicated that NLR has a negative association with NK cell activity in healthy donor[25], otherwise, Yang et al.[26] assume that inflammatory response contributed to NK cell anergy, and NK cell anergy was associated with higher NLR in pancreatic cancer; Kang et al.[27] also found a negative correlation between NK cell activity and NLR in gastric cancer, breast cancer, and pancreatic cancer. In addition, a negative correlation between CD8+ T cell and NLR was observed in intrahepatic cholangiocarcinoma[28], it is notable that increased CD8+ T cell was favorably associated with survival in HLH[29]. Taken together, it is reasonable to accept the prognostic value role of NLR in HLH.

However, the present study also has several limitations that need to be acknowledged. First, the study was uncontrolled and retrospective in nature. Second, as a single-center analysis, we did not use ROC to determine
the cutoff value of NLR for the prediction of mortality. Finally, HLH is a systematic syndrome, a single indicator may have a bias to evaluate prognosis. Future multicenter and prospective studies are required to overcome these limitations, and a prognostic scoring system is needed, our study may shed some light on it.

In conclusion, our current study emphasizes the potential role of NLR as prognostic factors for early death in HLH, suggests NLR could be used as a reference indicator for the monitoring and management of HLH.

**Patients And Methods**

**Patients**

The study collected a total of 92 patients from Sep 2014 to Dec 2019, in the hematology department, the Second Hospital of Anhui Medical University, and carried out according to the approval of the institutional review board and informed consent before patient enrollment. The clinical diagnosis was made according to the 2004 Histiocyte Society Criteria for HLH diagnosis (HLH-2004)[7]: (1) fever (≥ 38.5°C for ≥7 days); (2) splenomegaly; (3) cytopenias affecting at least two of three lineages (i.e., hemoglobin (HB) <90g/L, platelet count (PLT) <100×10^9/L, neutrophil count <1.0×10^9/L); (4) hypertriglyceridemia (≥3 mmol/L) and/or hypofibrinogenemia (≤1.5 g/L); (5) hemophagocytosis in bone marrow, spleen, liver, or lymphnodes; (6) hyperferritinemia (≥500 µg/L); (7) low or absent NK-cell activity; and (8) elevated level of serum soluble CD25 (i.e., soluble interleukin (IL)-2 receptor ≥2400 IU/mL). It is unavailable to finish the test for soluble CD25 levels and NK cell activity, so the diagnosis was made when the patient meets the five of six criteria.

The clinical data and the following laboratory data were collected at the time of the diagnosis: complete blood count (WBC, neutrophil, lymphocyte, HB, PLT), coagulation function (prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (FIB), D-Dimer), biochemical index (total bilirubin (TB), Triglyceride (TG), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (AKP), Serum Ferritin (SF), Glutamyltranspeptidase (Y-GT), Albumin (ALB), Creatinine (CR), lactate dehydrogenase (LDH) and C-reactive protein (CRP)).

**Statistical analysis**

The continuous variates are presents as median (min-max), Categorical variates are presents as frequencies (percentages). Student's T test and Mann–Whitney U test were used for continuous variates comparison when appropriate, and the Chisquare test was used for categorical variates. Univariate and multivariate analyses were performed with Cox regression. All variables with a P value less than 0.1 in the univariate analyses were included in multivariate analysis with a stepwise method to determine independent prognosis factors. Kaplan-Meier method was used for the survival curve.

All P values were two sided, and P values < 0.05 was determined to be statistically significant. All statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS version 19.0, USA).

**Abbreviations**

HLH: Hemophagocytic lymphohistiocytosis
NLR: Neutrophil-lymphocyte ratio
PLT: Platelet
HB: Hemoglobin
PT: Prothrombin time
IL: Interleukin
APTT: Activated partial thromboplastin time
FIB: Fibrinogen
TB: Total bilirubin,
TG: Triglyceride
AST: Aspartate aminotransferase
ALT: Alanine aminotransferase
AKP: Alkaline phosphatase
Y-GT: Glutamyltranspeptidase
SF: Serum Ferritin
ALB: Albumin
CR: Creatinine
LDH: Lactate dehydrogenase
CRP: C-reactive protein

**Declarations**

**Ethics approval and consent to participate**

All procedures were performed in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000.

**Consent for publication**

Written informed consent was obtained from the parents of all subjects included in the study.

**Availability of data and materials**
The datasets analyzed during the current study are available from the corresponding author on reasonable request.

**Competing interests**

All authors declare that they have no conflict of interest.

**Conflicts of interest:**

The authors declare that there is no conflict of interests regarding the publication of this paper

**Funding**

This work was supported by National Natural Science Foundation of China: [grant number 81670179]; and major subject of science and technology of Anhui province: [grant number 201903a07020030]

**Author contribution**

LHH, FW and YP assisted the patient, performed data collection, analyzed the data, wrote the manuscript and approved the final manuscript as submitted. CW, JKZ, QL wrote the manuscript. WWZ, CD, YM, HPW, SDX and ZMZ assisted the patient.

**Acknowledgements**

We thank all the medical and nursing staff in our hematology department for their valuable cooperation.

**Reference**

1. Al-Samkari, H. and N. Berliner, *Hemophagocytic Lymphohistiocytosis*. Annu Rev Pathol, 2018. **13**: p. 27-49.

2. Griffin, G., S. Shenoi, and G.C. Hughes, *Hemophagocytic lymphohistiocytosis: An update on pathogenesis, diagnosis, and therapy*. Best Pract Res Clin Rheumatol, 2020: p. 101515.

3. Schram, A.M. and N. Berliner, *How I treat hemophagocytic lymphohistiocytosis in the adult patient*. Blood, 2015. **125**(19): p. 2908-14.

4. Zhou, M., L. Li, Q. Zhang, S. Ma, J. Sun, L. Zhu, et al., *Clinical features and outcomes in secondary adult hemophagocytic lymphohistiocytosis*. QJM, 2018. **111**(1): p. 23-31.

5. Zhao, Y., D. Lu, S. Ma, L. Li, J. Zhu, Zhou, et al., *Risk factors of early death in adult patients with secondary hemophagocytic lymphohistiocytosis: a single-institution study of 171 Chinese patients*. Hematology, 2019. **24**(1): p. 606-612.

6. Trottestam, H., A. Horne, M. Arico, R.M. Egeler, A.H. Filipovich, H. Gadner, et al., *Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol*. Blood, 2011. **118**(17): p. 4577-84.

7. Henter, J.I., A. Horne, M. Arico, R.M. Egeler, A.H. Filipovich, S. Imashuku, et al., *HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis*. Pediatr Blood Cancer, 2007. **48**(2): p. 124-31.
8. Carter, S.J., R.S. Tattersall, and A.V. Ramanan, *Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment*. Rheumatology (Oxford), 2019. **58**(1): p. 5-17.

9. Li, X., H. Yan, X. Zhang, J. Huang, S.T. Xiang, Z. Yao, et al., *Elevated serum myoglobin levels at hospital admission and the risk of early death among patients with hemophagocytic lymphohistiocytosis: evidence from 155 pediatric patients*. Ann Hematol, 2020. **99**(5): p. 963-971.

10. Templeton, A.J., M.G. McNamara, B. Seruga, F.E. Vera-Badillo, P. Aneja, A. Ocana, et al., *Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis*. J Natl Cancer Inst, 2014. **106**(6): p. dju124.

11. Cataudella, E., C.M. Giraffa, S. Di Marca, A. Pulvirenti, S. Alaimo, M. Pisano, et al., *Neutrophil-To-Lymphocyte Ratio: An Emerging Marker Predicting Prognosis in Elderly Adults with Community-Acquired Pneumonia*. J Am Geriatr Soc, 2017. **65**(8): p. 1796-1801.

12. Larmann, J., J. Handke, A.S. Scholz, S. Dehne, C. Arens, H.J. Gillmann, et al., *Preoperative neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are associated with major adverse cardiovascular and cerebrovascular events in coronary heart disease patients undergoing non-cardiac surgery*. BMC Cardiovasc Disord, 2020. **20**(1): p. 230.

13. Fan, L.L., Y.J. Wang, C.J. Nan, Y.H. Chen, and H.X. Su, *Neutrophil-lymphocyte ratio is associated with all-cause mortality among critically ill patients with acute kidney injury*. Clin Chim Acta, 2019. **490**: p. 207-213.

14. Huang, J., G. Yin, L. Duan, T. Tian, J. Xu, J. Wang, et al., *Prognostic Value of Blood-Based Inflammatory Biomarkers in Secondary Lymphohistiocytosis*. J Clin Immunol, 2020.

15. Yoon, S.E., Y. Eun, K. Huh, C.R. Chung, I.Y. Yoo, J. Cho, et al., *A comprehensive analysis of adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective cohort study*. Ann Hematol, 2020.

16. Arca, M., L. Fardet, L. Galicier, S. Riviere, C. Marzac, C. Aumont, et al., *Prognostic factors of early death in a cohort of 162 adult haemophagocytic syndrome: impact of triggering disease and early treatment with etoposide*. Br J Haematol, 2015. **168**(1): p. 63-8.

17. Han, B.K., K.D. Wysham, K.C. Cain, H. Tyden, A.A. Bengtsson, and C. Lood, *Neutrophil and lymphocyte counts are associated with different immunopathological mechanisms in systemic lupus erythematosus*. Lupus Sci Med, 2020. **7**(1).

18. Jung, J.Y., E. Lee, C.H. Suh, and H.A. Kim, *Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are associated with disease activity in polymyalgia rheumatica*. J Clin Lab Anal, 2019. **33**(9): p. e23000.

19. Huang, Z., Z. Fu, W. Huang, and K. Huang, *Prognostic value of neutrophil-to-lymphocyte ratio in sepsis: A meta-analysis*. Am J Emerg Med, 2020. **38**(3): p. 641-647.

20. Wang, J., X. Zhou, Y. Liu, Z. Li, and X. Li, *Prognostic significance of neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma: A meta-analysis*. PLoS One, 2017. **12**(4): p. e0176008.

21. Wang, S., Y. Ma, L. Sun, Y. Shi, S. Jiang, K. Yu, et al., *Prognostic Significance of Pretreatment Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio in Patients with Diffuse Large B-Cell Lymphoma*. Biomed Res Int, 2018. **2018**: p. 9651254.

22. Sun, H., J. Que, Y. Peng, H. Ye, H. Xiang, Y. Han, et al., *The neutrophil-lymphocyte ratio: A promising predictor of mortality in coronary care unit patients - A cohort study*. Int Immunopharmacol, 2019. **74**: p. 105692.
23. Turcato, G., F. Sanchis-Gomar, G. Cervellin, E. Zorzi, V. Sivero, G.L. Salvagno, et al., *Evaluation of Neutrophil-lymphocyte and Platelet-lymphocyte Ratios as Predictors of 30-day Mortality in Patients Hospitalized for an Episode of Acute Decompensated Heart Failure*. J Med Biochem, 2019. 38(4): p. 452-460.

24. Fujiwara, F., S. Hibi, and S. Imashuku, *Hypercytokinemia in hemophagocytic syndrome*. Am J Pediatr Hematol Oncol, 1993. 15(1): p. 92-8.

25. Kim, B.R., S. Chun, D. Cho, and K.H. Kim, *Association of neutrophil-to-lymphocyte ratio and natural killer cell activity revealed by measurement of interferon-gamma levels in a healthy population*. J Clin Lab Anal, 2019. 33(1): p. e22640.

26. Yang, C., H. Cheng, Y. Zhang, K. Fan, G. Luo, Z. Fan, et al., *Anergic natural killer cells educated by tumor cells are associated with a poor prognosis in patients with advanced pancreatic ductal adenocarcinoma*. Cancer Immunol Immunother, 2018. 67(12): p. 1815-1823.

27. Kang, H.J., K. Bae, J.H. Kim, C.K. Cho, and H.S. Yoo, *Correlation Between Natural Killer Cell Activity and Systemic Inflammatory Markers for Heterogeneous Cancer Patients Treated With Wheel Balance Cancer Therapy*. Integr Cancer Ther, 2018. 17(2): p. 322-331.

28. Lin, G., Y. Liu, S. Li, Y. Mao, J. Wang, Z. Shuang, et al., *Elevated neutrophil-to-lymphocyte ratio is an independent poor prognostic factor in patients with intrahepatic cholangiocarcinoma*. Oncotarget, 2016. 7(32): p. 50963-50971.

29. Dalal, B.I., A.P. Vakil, N.S. Khare, S.Y. Wang, M.J. Richards, and L.Y. Chen, *Abnormalities of the lymphocyte subsets and their immunophenotype, and their prognostic significance in adult patients with hemophagocytic lymphohistiocytosis*. Ann Hematol, 2015. 94(7): p. 1111-7.

**Tables**

**Table 1.** Clinical and laboratory parameters of patients according to survival status.
|                        | All patients | Survivor (n=53) | Nonsurvivor (n=39) | P value | NLR<2.99 (n=46) | NLR≥2.99 (n=46) | P value |
|------------------------|--------------|----------------|--------------------|---------|-----------------|-----------------|---------|
| Age (year)             | 50(16-88)    | 47(16-73)      | 58(19-88)          | 0.040*  | 46(16-88)       | 55.5(22-77)    | 0.020*  |
| Sex (male)             | 54(58.6%)    | 27(50.9%)      | 27(69.2%)          | 0.078   | 26(56.5%)       | 28(60.9%)      | 0.672   |
| NLR                    |              |                |                    |         |                 |                 |         |
| WBC (10^9/L)           | 2.81(0.34-43.86) | 2.88(0.36-43.86) | 2.30(0.34-15.30)   | 0.288   |                 |                 |         |
| N (10^9/L)             | 1.48(0.05-14.59) | 1.38(0.1-11.83) | 1.57(0.05-14.59)   | 0.847   |                 |                 |         |
| L (10^9/L)             | 0.62(0.02-18.98) | 0.84(0.1-18.98) | 0.41(0.02-1.84)    | 0.001*  |                 |                 |         |
| H (10^9/L)             | 2.99(0.04-41.28) | 2.04(0.04-25.24) | 4.38(0.18-41.28)   | 0.005*  |                 |                 |         |
| HB (g/L)               | 83(23-141)   | 81(43-141)     | 85(23-130)         | 0.853   | 74.5(43-130)    | 89(23-141)     | 0.008   |
| PLT (10^9/L)           | 43.5(3-687)  | 45(8-687)      | 38(3-99)           | 0.019*  | 37.5(3-150)     | 48.5(15-281)   | 0.085   |
| TB (µmol/L)            | 20.7(2.1-233.2) | 20.4(2.1-106.6) | 24.1(3.3-233.2)    | 0.136   | 22.5(2.1-233.2) | 20.6(5.7-139.3) | 0.800   |
| TG (mmol/L)            | 2.45(0.61-65.30) | 2.48(0.61-65.30) | 2.35(0.75-11.46)   | 0.890   | 2.31(0.61-31.10) | 2.71(0.75-65.30) | 0.725   |
| PT (s)                 | 13.3(9.9-29.5) | 12.9(9.9-18.0) | 15.0(10.4-29.5)    | 0.005*  | 12.9(9.9-17.9)  | 14.1(11.6-29.5) | 0.010   |
| APTT (s)               | 39.5(21-177) | 35.3(21-64)    | 46.4(21-177)       | 0.002*  | 39.5(21-75)     | 40.4(21-177)   | 0.355   |
| FIB (g/L)              | 1.53(0.33-7.19) | 1.65(0.34-7.19) | 1.30(0.33-6.16)    | 0.024*  | 1.58(0.50-6.96) | 1.43(0.33-7.19) | 0.755   |
| D-D                    | 4.5(0.47-80.00) | 4.51(0.55-35.00) | 4.10(0.47-35.00)   | 0.873   | 3.49(0.55-40.00) | 5.82(0.47-80.00) | 0.171   |
| ALT (U/L)              | 70.5(8-4310) | 70(8-687)      | 77(15-4310)        | 0.684   | 73.5(15-687)    | 68.5(8-4310)   | 0.470   |
| AST (U/L)              | 109.5(3-5579) | 103(3-1104)    | 131(28-5579)       | 0.180   | 119(3-1356)     | 103.5(14-5579) | 0.910   |
| AKP (U/L)              | 141(34-2582) | 120(34-1799)   | 162.5(38-2582)     | 0.174   | 143(34-1799)    | 131.5(38-2582) | 0.562   |
| Y-GT                   | 98(7-700)    | 85.5(7-700)    | 130(12-631)        | 0.440   | 88.5(7-700)     | 101(10-698)    | 0.767   |
| SF (ng/ml)             | 4595(171-212133) | 4590(175-212133) | 7180(171-117000)   | 0.627   | 4495(171-138000) | 7350(749-212133) | 0.229   |
|             |        |        |        |        |        |        |        |
|-------------|--------|--------|--------|--------|--------|--------|--------|
| ALB (g/L)   | 26(13-41.6) | 27.3(15-37.6) | 23.6(13.0-41.6) | 0.008* | 26.7(16.2-35.5) | 24.4(13.0-41.6) | 0.094 |
| CR (mol/l)  | 69(28-1044) | 67(32-1044) | 81(28-407) | 0.017* | 66(34-267) | 78.5(28-1044) | 0.027* |
| LDH (U/L)   | 781.5(100-10873) | 627(100-6480) | 1053(196-10873) | 0.035* | 648(100-3187) | 841.5(196-10873) | 0.639 |
| CRP (mg/L)  | 37.8(0.5-244.7) | 37.3(0.5-244.7) | 38.3(0.9-123.6) | 0.874 | 29.1(0.5-183.26) | 51.9(2.5-244.7) | 0.016* |
| IL-6        | 40.0(1.6-5000.0) | 39.0(1.6-1753.0) | 43.5(4.0-5000.0) | 0.721 | 27.0(3.9-1753.0) | 61.2(1.6-5000.0) | 0.008* |
| splenomegaly | 66    | 4381.1% | 2359.0% | 0.020* | 3780.4% | 2963.0% | 0.064 |
| hepatomegaly | 22   | 1426.4% | 820.5% | 0.512 | 1430.4% | 715.2% | 0.092 |
| enlarged lymph nodes | 41 | 2343.4% | 1846.2% | 0.793 | 2145.7% | 2043.5% | 0.834 |
| Triggering condition | 0.096 |        |        |        |        |        | 0.135 |
| malignancy  | 48    | 28    | 20    | 24    | 24    |        |        |
| Infections  | 27    | 17    | 10    | 17    | 10    |        |        |
| Autoimmune disorders | 10  | 7     | 3     | 2     | 8     |        |        |
| Unknow      | 7     | 1     | 6     | 3     | 4     |        |        |

*represent P<0.05

Table 2. Univariate Cox regression analysis
| Factors                  | HR  | 95% CI      | P   |
|-------------------------|-----|-------------|-----|
| age≥ 50 (year)          | 1.627 | 0.859-3.083 | 0.135 |
| Sex (male)              | 1.740 | 0.881-3.435 | 0.111 |
| WBC≥ 2.81 (109/L)       | 0.983 | 0.542-1.842 | 0.957 |
| N≥ 1.48 (109/L)         | 1.100 | 0.587-2.062 | 0.765 |
| L≥ 0.62 (109/L)         | 0.427 | 0.219-0.833 | 0.012* |
| NLR≥ 2.99               | 2.396 | 1.230-4.669 | 0.010* |
| HB≥ 83 (g/L)            | 1.201 | 0.640-2.255 | 0.568 |
| PLT≥ 43 (109/L)         | 0.212 | 0.355-1.259 | 0.212 |
| PT≥ 13.3 (s)            | 2.620 | 1.303-5.269 | 0.007* |
| APTT≥ 39.5 (s)          | 2.701 | 1.366-5.340 | 0.004* |
| FIB≥ 1.53 (g/L)         | 0.620 | 0.328-1.175 | 0.143 |
| ALB≥ 26 (g/L)           | 0.346 | 0.175-0.685 | 0.002* |
| CR ≥ 69 (mol/l)         | 1.718 | 0.901-3.278 | 0.100 |
| LDH ≥ 781 (U/l)         | 1.791 | 0.945-3.392 | 0.074 |
| AST≥ 109.5(U/L)         | 1.200 | 0.639-2.252 | 0.571 |
| ALT≥ 70.5(U/L)          | 1.093 | 0.583-2.047 | 0.782 |
| AKP≥ 141(U/L)           | 1.258 | 0.670-2.361 | 0.476 |
| Y-GT≥ 98                | 1.195 | 0.636-2.245 | 0.579 |
| TB≥ 20.7(µmol/L)        | 1.338 | 0.712-2.512 | 0.365 |
| TG≥ 2.45(mmol/L)        | 1.951 | 0.508-1.783 | 0.876 |
| CRP≥ 37.8 (mg/L)        | 1.020 | 0.544-1.911 | 0.952 |
| IL-6≥ 40.0              | 1.032 | 0.551-1.933 | 0.922 |
| Etoposide               | 0.771 | 0.390-1.523 | 0.454 |

*represent P<0.05

**Table 3.** Multivariate Cox regression analysis
| Factors | HR   | 95%CI          | P    |
|---------|------|---------------|------|
| NLR ≥ 2.99 | 2.508 | 1.275-4.934   | 0.008* |
| APTT ≥ 39.5(s) | 2.780 | 1.395-5.542   | 0.004* |
| Albumin ≥ 26 (g/L) | 0.384 | 0.192-0.768   | 0.008* |

*represent P<0.05

**Figures**

**Figure 1**

Main triggering condition distribution in all patients, and distribution according to gender and age.
Figure 2

Kaplan-Meier curve according to NLR (A), Albumin (B) and APTT (C).